Advice
in the absence of a submission from the holder of the marketing authorisation
canakinumab (Ilaris ®) 150 mg/ml, powder for solution for injection is not recommended for use within NHSScotland.
Indication under review: Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents and children aged 4 years and older with body weight above 15 kg.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result SMC cannot recommend its use within NHSScotland.
Download detailed advice71KB (PDF)
Medicine details
- Medicine name:
- canakinumab (Ilaris)
- SMC ID:
- 658/10
- Indication:
- Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents and children aged 4 years and older with body weight above 15 kg.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 November 2010